Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baiya SARS-CoV-2 Vax 1 Phase 1 in Healthy Adults
NCT04953078Phase 1Completed
- Sponsor
- Baiya Phytopharm
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Baiya SARS-CoV-2 Vax 1 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Baiya Phytopharm. Primary endpoints: Frequency and Grade of Solicited Adverse Events, Frequency and Grade of Adverse Events and 3 more. Started Sep 2021; status: completed.
02
Drugs
Baiya SARS-CoV-2 Vax 1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04953078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04953078.